Hook / Thesis
HealthEquity is the dominant custodian in the HSA market and is showing the sort of steady, cash-generative growth that should appeal to investors who want a blend of growth and capital efficiency. The company reported fiscal metrics that matter: HSA accounts reached 10.6 million (up 7%), total accounts hit 17.8 million, HSA assets grew 14% to $36.5 billion and HSA investments jumped 26% to $18.5 billion. Those are not incremental line items - they are the raw fuel for recurring fee revenue, investment spread, and higher-margin services.
Price action has already priced in some of last years risks: shares trade around $83.68 today and recently reset from a 52-week high of $116.65 to a low of $72.76. That reset left an attractive entry window where the business still composes compelling cash flow with an enterprise value of roughly $7.71 billion and free cash flow of $408.6 million. My stance: upgrade to a long trade with a disciplined entry at $83.50, a stop at $75.00, and a target of $100.00 over a long-term horizon (180 trading days).
Business overview - why the market should care
HealthEquity operates technology-enabled services around healthcare spending, most notably Health Savings Accounts (HSAs). Its competitive position is simple: scale and a distribution network that feeds ongoing account additions and asset growth. HSAs are sticky; once an account-holder accumulates assets and starts investing, they become less likely to switch custodians. That makes growth in accounts and invested balances a high-value outcome.
From a fundamental perspective, three drivers matter:
- Account growth - 10.6M HSAs and 17.8M total accounts creates a large recurring-fee base that grows with payroll and plan adoption.
- Assets under administration and invested balances - $36.5B of HSA assets and $18.5B invested balances drive fee revenue and higher economics per account.
- Cash generation - the business converts to free cash flow efficiently; reported free cash flow is $408.6M, which supports reinvestment and optional capital returns.
Supporting numbers
Concrete metrics to keep top of mind:
| Metric | Value |
|---|---|
| Current price | $83.68 |
| Market cap | $7.07B |
| Enterprise value | $7.71B |
| Free cash flow | $408.61M |
| HSA assets | $36.5B (up 14%) |
| HSA investments | $18.5B (up 26%) |
| HSAs (accounts) | 10.6M (up 7%) |
| P/E (TTM) | ~33 |
| Price / Sales | ~5.38 |
Valuation framing
At roughly $7.07 billion market cap and an enterprise value near $7.71 billion, HealthEquity is trading at price-to-free-cash-flow near the high-teens and a P/E in the low 30s. That multiple is not cheap in absolute terms, but it reflects a hybrid business: predictable, recurring-fee revenue from account servicing mixed with high-margin investment flow and fintech SaaS-like operating leverage. The free cash flow of ~$408.6M implies an EV/FCF in the high teens - reasonable for a company that can grow invested balances and account penetration, but it does require execution to justify multiple expansion.
History-wise, shares peaked at $116.65 in 2025 and fell materially on cyber and fraud headlines earlier in 2025. The reset compresses valuation and, if the company continues to show account and asset growth alongside margin stabilization, multiple expansion back toward its prior range is plausible.
Catalysts (what will drive the trade)
- Continued HSA account additions and dollar inflows - record Q4 new HSA sales and more than 1M new accounts in the fiscal year provide the organic growth engine.
- Higher mix of invested balances - a 26% increase in HSA investments translates to higher fee yields and margins.
- Margin leverage and FCF stability - sustained free cash flow near $400M supports investor-friendly moves (buybacks, reinvestment) and reduces downside volatility.
- Product traction - adoption of AI-powered educational tools and improved digital engagement could increase wallet share per account.
Trade plan - actionable and time-defined
This is a long trade with a principal thesis that account and asset growth will re-rate the stock as cyber risks fade and margins normalize. Specifics:
- Entry: Buy at $83.50. The idea is to enter slightly below the intraday print to avoid chasing strength.
- Stop loss: $75.00. This caps downside and sits below recent support near the low-$70s; if shares break below $75, the thesis of account-driven re-rating weakens materially.
- Target: $100.00. This target represents an upside of ~20% from entry and reflects reasonable multiple expansion if growth and margin trends continue.
- Horizon: Long term (180 trading days). I expect the drivers to unfold over several quarters: account additions, asset growth and improved investment penetration take time to move financials and sentiment.
For more active traders who prefer shorter horizons: a mid-term (45 trading days) target could be $92-$94 if near-term results and guidance reaffirmation surprise positively. For short-term traders (10 trading days) focus on intraday momentum and technical support, but be aware that fundamental catalysts here play out over months not days.
Technical context
Technicals are neutral-to-constructive: the 10- and 20-day SMAs sit slightly below current price and RSI sits around 55, indicating room to run before overbought conditions. MACD momentum shows a mild bearish histogram but that can flip quickly on upbeat results or guidance. Short interest has trended down from higher peaks, but short-volume spikes appear periodically, so expect occasional volatility and intraday pinch points.
Risks and counterarguments
At least four clear risks can derail this trade, and they deserve attention:
- Cybersecurity and fraud risk - the company has previously disclosed increased criminal activity targeting its systems. A material breach or a new wave of fraud losses could re-open the valuation gap and materially compress multiples.
- Slowing HSA adoption - HSAs are driven by employer plan design and regulatory regimes. If employer adoption slows or plan designs change (e.g., lower HSA contributions), account growth and asset flows could decelerate.
- Execution risk on investments - higher invested balances are a key margin lever. Underperformance of investment offerings, lower yields, or reduced investor appetite would hit fees and economics.
- Valuation sensitivity - the stock is not cheap; multiple compression due to a broader risk-off environment or rising interest rates could cause share price weakness even if fundamentals remain stable.
- Regulatory / legal risk - operating in financial services invites regulatory scrutiny. Any unfavorable regulatory changes or litigation could be costly.
Counterargument: Some investors will argue that valuation remains rich for a company with P/E in the low-30s and price-to-free-cash-flow in the high teens, especially after a period of headlines around cybersecurity. That view is reasonable: you are paying for execution and margin improvement. If account growth stalls or the company fails to convert assets into higher-margin investment revenue, the multiple could compress further. This trade accepts that risk because the current price includes a meaningful discount from 2025 highs and the company still produces robust free cash flow.
Conclusion - stance and what would change my mind
I am upgrading HealthEquity to a long trade with a disciplined entry at $83.50, a stop at $75.00 and a $100 target over 180 trading days. The upside is driven by continued account additions, a rising share of invested balances and stable to improving margin and FCF conversion. The companys scale in HSAs, recent record new HSA sales and the $18.5B invested balance create a credible pathway to both revenue and margin expansion.
What would change my mind? Three developments would force a reassessment: (1) a material new cybersecurity incident or evidence of persistent fraud that undermines trust and increases remediation costs; (2) multi-quarter slowdown in HSA account additions and invested balance growth; (3) evidence that invested balances are not monetizing as expected (for example, lower fee yields or loss of investment flows). Any of these would push me to trim or exit the position.
Key monitoring checklist - items to watch while holding this trade:
- Quarterly HSA account growth and invested balances (watch for continued mid-teens growth in investments).
- Free cash flow and operating margin trends.
- Any corporate announcements about cybersecurity hardening, insurance recoveries, or litigation outcomes.
- Short interest and short-volume spikes that could create intra-day volatility.
Trade summary: Buy HQY at $83.50, stop $75.00, target $100.00, long-term (180 trading days). Position size to be determined by risk tolerance; respect the stop and treat the thesis as dependent on continued account and asset growth.